Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
about
Cell therapies for pancreatic beta-cell replenishmentMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersEmergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterialsMolecular mechanism underlying lymphatic metastasis in pancreatic cancerHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsMUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progeniesNew promising drug targets in cancer- and metastasis-initiating cells.Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrencePotential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.Propyl gallate inhibits adipogenesis by stimulating extracellular signal-related kinases in human adipose tissue-derived mesenchymal stem cells.Properties of mechano-transduction via simulated microgravity and its effects on intracellular trafficking of VEGFR'sGreat promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapiesEpigenetic gene regulation in stem cells and correlation to cancerRecent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications.Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.APC haploinsufficiency coupled with p53 loss sufficiently induces mucinous cystic neoplasms and invasive pancreatic carcinoma in mice.
P2860
Q26741240-34FA167E-E17C-44C1-9CF8-4E8F478926ECQ26822406-7811FD0F-CBE7-438A-A7D7-DDC6E6841A29Q26860518-1355AF85-CA06-4AF4-993A-D094F6F53E29Q26999345-473A6CF8-A97D-4DA1-8FA5-D710FA3329F9Q28393898-7EFAE475-8A15-4D0A-BD14-4C3E54F4452EQ33938044-26849EE7-D906-47D7-80DF-86611297EE2BQ34003691-AB2AF432-731F-4167-AC33-A0E3F47BB78AQ34244929-BACC946F-C553-4D8E-BC37-E80BDC97CCC7Q34382586-3FA5BC38-CDAB-4B76-B4C5-146A695BC086Q34382914-9FC7237A-A0BA-43E2-A502-AB96B67C8806Q35225869-77060B66-908C-496D-9034-1A5B4261FCE6Q35450793-3ADEFED5-66EF-44E5-9B4E-53F90CDB530FQ36050692-37A9DC9A-089D-42C5-AE26-33E984C74767Q36819400-501954B9-0982-4AA3-9BC8-F5332F5646C3Q37251747-5E5418AC-0A45-4CC9-BB9A-FF4620220412Q37310063-9265D298-219E-420F-B8FE-D7B5B3D9AF1DQ37610799-19CE8D7A-7DA6-412A-912E-4B1099CACB19Q38962257-4AC9F1C9-4085-49BE-8E4E-5BF575610236Q50930888-52267A1E-FA31-4B4C-A165-4822A53C48C0
P2860
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Recent progress on normal and ...... aggressive pancreatic cancer.
@ast
Recent progress on normal and ...... aggressive pancreatic cancer.
@en
type
label
Recent progress on normal and ...... aggressive pancreatic cancer.
@ast
Recent progress on normal and ...... aggressive pancreatic cancer.
@en
prefLabel
Recent progress on normal and ...... aggressive pancreatic cancer.
@ast
Recent progress on normal and ...... aggressive pancreatic cancer.
@en
P2860
P356
P1433
P1476
Recent progress on normal and ...... aggressive pancreatic cancer.
@en
P2093
P2860
P304
P356
10.1136/GUT.2008.150052
P407
P577
2008-10-01T00:00:00Z